Functional and metabolic recovery of the right ventricle during Bosentan therapy in idiopathic pulmonary arterial hypertension.
An impaired high-energy phosphate metabolism might play a critical role in the pathogenesis of right ventricular (RV) failure due to chronic pulmonary arterial hypertension (PAH). 31P-NMR spectroscopy is well established for measurements of high-energy phosphate metabolites in various left ventricular heart diseases, however, mainly for technical and sensitivity reasons, its successful transfer for measurements in the RV is currently missing. In the present study, the usefulness of this non-invasive approach is not only shown in RV failure due to PAH but also tested during subsequent therapy.
Spindler
Matthias
M
Department Internal Medicine I/Center of Cardiovascular Medicine, University Würzburg, Würzburg, Germany. spindler_m@medizin.uni-wuerzburg.de
Schmidt
Michael
M
Geier
Oliver
O
Sandstede
Jörn
J
Hahn
Dietbert
D
Ertl
Georg
G
Beer
Meinrad
M
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D013318:Stroke Volume / Q000187:drug effects; D013449:Sulfonamides / Q000627:therapeutic use*; D018497:Ventricular Dysfunction, Right / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*; D016278:Ventricular Function, Right / Q000187:drug effects*
D000959:Antihypertensive Agents; D010710:Phosphates; D013449:Sulfonamides; D000077300:Bosentan